Saturday, June 20, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 381 of 1,261
  1. US 10849885

    Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy

    PTC THERAPEUTICS, INC. · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  2. US 10849911

    Low dose compositions of Aramachol salts

    GALMED RESEARCH AND DEVELOPMENT LTD · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  3. US 10849912

    Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  4. US 10851072

    Inhibitors of Rho/MRTF/SRF-mediated gene transcription and methods for use of the same

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  5. US 10851110

    Heterocyclic inhibitors of PTPN11

    The Board of Regents of the University of Texas System · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  6. US 10851377

    Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder

    Alnylam Pharmaceuticals, Inc. · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  7. US 10849935

    Method to suppress the systemic toxicity of chemotherapeutic drugs

    UNITED ARAB EMIRATES UNIVERSITY · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  8. US 10849988

    Hydrogel for engineered immune response to D-chirality peptides

    The Regents of the University of California · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  9. US 10851158

    Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  10. US 10852220

    Methods and devices for high throughput purification

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  11. US 10851463

    Membrane template synthesis of microtube engines

    The Regents of the University of California · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  12. US 10851367

    Tissue-specific genome engineering using CRISPR-Cas9

    The Regents of the University of California · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  13. US 10851412

    Cell potency assay for therapeutic potential

    Fate Therapeutics, Inc. · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  14. US 10851358

    Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome

    Precision BioSciences, Inc. · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  15. US 10851173

    Anti-OX40 antibodies and methods of using the same

    The Board of Regents of the University of Texas System · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  16. US 10851115

    Heterocyclic compounds as RSV inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  17. US 10851112

    Anti-HCMV virus compound

    Medshine Discovery Inc. · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  18. US 10851146

    Method for preparing liraglutide intermediate polypeptide

    AMPHASTAR NANJING PHARMACEUTICALS INC · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  19. US 10851101

    Compounds for treating spinal muscular atrophy

    PTC THERAPEUTICS, INC. · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  20. US 10851102

    Imidazole and triazole containing bicyclic compounds as JAK inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  21. US 10851093

    Tyrosine kinase inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  22. US 10851088

    Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production

    DENALI THERAPEUTICS INC. · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  23. US 10851104

    Valbenazine salts and polymorphs thereof

    Neurocrine Biosciences, Inc. · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  24. US 10851103

    Valbenazine salts and polymorphs thereof

    Neurocrine Biosciences, Inc. · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.